- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Fab-12 variant Y0317 | Lucentis® | muMAb VEGF A.4.6.1 | rhuFab V2
ranibizumab is an approved drug (FDA (2006), EMA (2007))
Compound class: Antibody
Comment: Ranibizumab is a Fab fragment of a monoclonal antibody designed to target vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody derivative are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals that ranibizumab sequences are claimed in patent WO1998045331 (clone Y0317) , with an expected affinity similar to clone Y0313-1. It is the Fab fragment of bevacizumab.
1. Baca M, Chen Y M-Y, Lowman HB, Presta LG, Wells JA. (1998)
Patent number: WO1998045331. Assignee: Genentech Inc,. Priority date: 07/04/1997. Publication date: 15/10/1998.
2. Baca M, Chen YM-Y, Lowman HB, Presta LG, Wells JA. (1998)
Patent number: WO1998045331. Assignee: Genentech Inc.. Priority date: 07/04/1997. Publication date: 15/10/1998.
3. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. (2005)
Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
Invest Ophthalmol Vis Sci, 46 (2): 726-33. [PMID:15671306]